Radiolabelled peptides have shown to be an important class of radiopharmaceuticals for imaging and therapy of malignancies expressing receptors of regulatory peptides. These peptides have high affinity and specificity for their receptors. The majority of these receptors are present at different levels in different tissues and turnours. This review focuses on the application of regulatory peptides radiolabelled with 67/68Ga, 90Y, 111In or 177Lu. Due attention is given to the current status of research, limitations and future perspectives of the application of these radiolabelled peptides for imaging and radiotherapy. It also covers elements of the basic science and preclinical and clinical aspects in general, however, mostly based on somatostatin receptor-mediated imaging and therapy. Now analogues, chelators, radionuclides and combinations thereof are discussed.

, , , , , , , , , , , ,
doi.org/10.2174/187152007780618171, hdl.handle.net/1765/74882
Anti-Cancer Agents in Medicinal Chemistry
Department of Internal Medicine

Breeman, W., Kwekkeboom, D. J., de Blois, E., de Jong, M., Visser, T., & Krenning, E. (2007). Radiolabelled regulatory peptides for imaging and therapy. Anti-Cancer Agents in Medicinal Chemistry (Vol. 7, pp. 345–357). doi:10.2174/187152007780618171